NCT01485302View on ClinicalTrials.gov

Single and Repeated Dosing Study to Assess the Safety and the Concentration-time Profile of SAR228810 in Alzheimer's Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Alzheimer's Disease
Interventions
DRUG

SAR228810

"Pharmaceutical form:solution~Route of administration: intravenous"

DRUG

SAR228810

"Pharmaceutical form:solution~Route of administration: subcutaneous"

Trial Locations (8)

1612

Investigational Site Number 100001, Sofia

9301

Investigational Site Number 710001, Bloemfontein

14186

Investigational Site Number 752001, Stockholm

21224

Investigational Site Number 752003, Malmo

31059

Investigational Site Number 250002, Toulouse

43141

Investigational Site Number 752002, Mölndal

69310

Investigational Site Number 250001, Pierre-Bénite

2333 CL

Investigational Site Number 528001, Leiden

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT01485302 - Single and Repeated Dosing Study to Assess the Safety and the Concentration-time Profile of SAR228810 in Alzheimer's Patients | Biotech Hunter | Biotech Hunter